These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 15134516)

  • 1. New developments on thromboxane and prostacyclin modulators part I: thromboxane modulators.
    Dogné JM; de Leval X; Hanson J; Frederich M; Lambermont B; Ghuysen A; Casini A; Masereel B; Ruan KH; Pirotte B; Kolh P
    Curr Med Chem; 2004 May; 11(10):1223-41. PubMed ID: 15134516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From the design to the clinical application of thromboxane modulators.
    Dogné JM; Hanson J; de Leval X; Pratico D; Pace-Asciak CR; Drion P; Pirotte B; Ruan KH
    Curr Pharm Des; 2006; 12(8):903-23. PubMed ID: 16533159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New developments on thromboxane and prostacyclin modulators part II: prostacyclin modulators.
    de Leval X; Hanson J; David JL; Masereel B; Pirotte B; Dogné JM
    Curr Med Chem; 2004 May; 11(10):1243-52. PubMed ID: 15134517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiplatelet effect of NQ12: a possible mechanism through the arachidonic acid cascade.
    Jin YR; Han XH; Lee JJ; Lim Y; Kim TJ; Yoo HS; Hong JT; Lee CK; Yun YP
    J Pharmacol Sci; 2007 Oct; 105(2):193-200. PubMed ID: 17951980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thromboxane synthase inhibitors and thromboxane A2 receptor antagonists: a quantitative structure activity relationships (QSARs) analysis.
    Kontogiorgis C; Hadjipavlou-Litina D
    Curr Med Chem; 2010; 17(28):3162-214. PubMed ID: 20666724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New trends in thromboxane and prostacyclin modulators.
    Dogné JM; de Leval X; Delarge J; David JL; Masereel B
    Curr Med Chem; 2000 Jun; 7(6):609-28. PubMed ID: 10702629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin.
    Bertele V; De Gaetano G
    Eur J Pharmacol; 1982 Dec; 85(3-4):331-3. PubMed ID: 6295787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New developments on thromboxane modulators.
    Dogné JM; Hanson J; de Leval X; Masereel B; Kolh P; Pirotte B
    Mini Rev Med Chem; 2004 Aug; 4(6):649-57. PubMed ID: 15279599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation.
    Li P; Fukuhara M; Diz DI; Ferrario CM; Brosnihan KB
    J Pharmacol Exp Ther; 2000 Jan; 292(1):238-46. PubMed ID: 10604953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An antithrombotic agent, NQ301, inhibits thromboxane A2 receptor and synthase activity in rabbit platelets.
    Jin YR; Cho MR; Lee KS; Lee JJ; Lim Y; Han XH; Oh KW; Hong JT; Yoo HS; Yun YP
    Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):162-7. PubMed ID: 16128910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of original dual thromboxane A2 modulators as antiangiogenic agents.
    de Leval X; Dassesse T; Dogné JM; Waltregny D; Bellahcène A; Benoit V; Pirotte B; Castronovo V
    J Pharmacol Exp Ther; 2006 Sep; 318(3):1057-67. PubMed ID: 16720756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
    Yu SM; Wu TS; Teng CM
    Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacological action on the thromboxane and prostacyclin balance in the body].
    Lakin KM; Makarov VA; Novikova NV; Tret'iak VM; Rukazenkov IuE
    Farmakol Toksikol; 1984; 47(2):67-79. PubMed ID: 6425078
    [No Abstract]   [Full Text] [Related]  

  • 14. Competitive antagonism at thromboxane receptors in human platelets.
    Armstrong RA; Jones RL; Peesapati V; Will SG; Wilson NH
    Br J Pharmacol; 1985 Mar; 84(3):595-607. PubMed ID: 2580580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The protective effects of paclitaxel on platelet aggregation through the inhibition of thromboxane A2 synthase.
    Lee JJ; Yu JY; Lee JH; Zhang WY; Kim TJ; Myung CS; Yun YP
    Arch Pharm Res; 2010 Mar; 33(3):387-94. PubMed ID: 20361303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological evaluation of both enantiomers of (R,S)-BM-591 as thromboxane A2 receptor antagonists and thromboxane synthase inhibitors.
    Rolin S; Dogne JM; Vastersaegher C; Hanson J; Masereel B
    Prostaglandins Other Lipid Mediat; 2004 Oct; 74(1-4):75-86. PubMed ID: 15560117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological evaluation of the novel thromboxane modulator BM-567 (II/II). Effects of BM-567 on osteogenic sarcoma-cell-induced platelet aggregation.
    de Leval X; Benoit V; Delarge J; Julémont F; Masereel B; Pirotte B; Merville MP; David JL; Dogné JM
    Prostaglandins Leukot Essent Fatty Acids; 2003 Jan; 68(1):55-9. PubMed ID: 12538091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 7-Oxabicyclo[2.2.1]heptane analogs as modulators of the thromboxane A2 and prostacyclin receptors.
    Sprague PW; Heikes JE; Harris DN; Greenberg R
    Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():337-43. PubMed ID: 6303073
    [No Abstract]   [Full Text] [Related]  

  • 19. The biochemical pharmacology of thromboxane synthase inhibition in man.
    FitzGerald GA; Reilly IA; Pedersen AK
    Circulation; 1985 Dec; 72(6):1194-201. PubMed ID: 3905048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prostacyclin--thromboxane A2 balance: pathophysiological and therapeutic implications.
    Bunting S; Moncada S; Vane JR
    Br Med Bull; 1983 Jul; 39(3):271-6. PubMed ID: 6354352
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.